Tema Etfs LLC Makes New Investment in Cencora, Inc. $COR

Tema Etfs LLC bought a new stake in Cencora, Inc. (NYSE:COR) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 6,520 shares of the company’s stock, valued at approximately $2,038,000.

Several other large investors have also modified their holdings of COR. Atlantic Edge Private Wealth Management LLC raised its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its position in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Caldwell Trust Co bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $46,000. Salomon & Ludwin LLC increased its holdings in shares of Cencora by 638.1% in the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after acquiring an additional 134 shares during the last quarter. Finally, Capital A Wealth Management LLC raised its position in shares of Cencora by 3,975.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after acquiring an additional 159 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 1.9%

COR opened at $342.11 on Tuesday. The stock’s 50 day moving average price is $349.92 and its 200 day moving average price is $318.78. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The stock has a market cap of $66.37 billion, a P/E ratio of 43.03, a P/E/G ratio of 1.60 and a beta of 0.66. Cencora, Inc. has a 12 month low of $233.61 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 30.19%.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the transaction, the chief executive officer owned 68,059 shares in the company, valued at approximately $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 20,317 shares of company stock valued at $7,009,260. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on COR. Robert W. Baird set a $392.00 target price on shares of Cencora in a research note on Tuesday, December 16th. UBS Group boosted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. TD Cowen upped their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Finally, Barclays started coverage on Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $379.50.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.